Serum advanced glycation end products as a putative biomarker in Type2 DKD patients' prognosis.

ABSTRACT:

Aim

Advanced glycation end products (AGEs) are pivotal mediators in diabetic kidney disease (DKD). However, their prognostic utility remains underexplored. This study introduced corrected lgAGEs [novel biomarker derived by adjusting logarithmically transformed AGEs (lgAGEs) levels based on serum albumin (ALB) levels] to enhance the prediction of adverse renal outcomes in patients with type 2 DKD (T2DKD).

Methods

In this prospective cohort study, 196 T2DKD patients were followed up longitudinally. Serum AGEs levels were log-transformed and adjusted for ALB to calculate corrected lgAGEs. Participants were stratified into the high- and low-level groups based on the median corrected lgAGEs. The association between corrected lgAGEs and renal outcomes was assessed using Cox propor

SUBMITTER: Wang ZH 

PROVIDER: S-EPMC11825471 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature